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ABSTRACT.  23 
Selection of effective genes that accurately predict chemotherapy response could 24 
improve cancer outcomes. We compare optimized gene signatures for cisplatin, 25 
carboplatin, and oxaliplatin response in the same cell lines, and respectively validate 26 
each with cancer patient data. Supervised support vector machine learning was used to 27 
derive gene sets whose expression was related to cell line GI50 values by backwards 28 
feature selection with cross-validation. Specific genes and functional pathways 29 
distinguishing sensitive from resistant cell lines are identified by contrasting signatures 30 
obtained at extreme vs. median GI50 thresholds. Ensembles of gene signatures at 31 
different thresholds are combined to reduce dependence on specific GI50 values for 32 
predicting drug response. The most accurate gene signatures for each platin are: 33 
cisplatin: BARD1, BCL2, BCL2L1, CDKN2C, FAAP24, FEN1, MAP3K1, MAPK13, 34 
MAPK3, NFKB1, NFKB2, SLC22A5, SLC31A2, TLR4, TWIST1; carboplatin: AKT1, 35 
EIF3K, ERCC1, GNGT1, GSR, MTHFR, NEDD4L, NLRP1, NRAS, RAF1, SGK1, TIGD1, 36 
TP53, VEGFB, VEGFC; oxaliplatin: BRAF, FCGR2A, IGF1, MSH2, NAGK, NFE2L2, 37 
NQO1, PANK3, SLC47A1, SLCO1B1, UGT1A1. TCGA bladder, ovarian and colorectal 38 
cancer patients were used to test cisplatin, carboplatin and oxaliplatin signatures 39 
(respectively), resulting in 71.0%, 60.2% and 54.5% accuracy in predicting disease 40 
recurrence and 59%, 61% and 72% accuracy in predicting remission. One cisplatin 41 
signature predicted 100% of recurrence in non-smoking bladder cancer patients (57% 42 
disease-free; N=19), and 79% recurrence in smokers (62% disease-free; N=35). This 43 
approach should be adaptable to other studies of chemotherapy response, independent 44 
of drug or cancer types. 45 
 46 
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INTRODUCTION 50 
Chemotherapy regimens are selected based on overall outcomes for specific 51 
types and subtypes of cancer pathology, progression to metastasis, other high-risk 52 
indications, and prognosis1,2, and variability in tumor resistance has led to tiered 53 
sequential strategies for selection of agents based on their overall efficacy3. We and 54 
others have developed machine learning (ML)-based gene signatures (i.e. predictive 55 
models) aimed at predicting response to specific chemotherapeutic agents and 56 
minimizing chemoresistance based on inhibition of growth or drug targets (GI50 or IC50)4–57 
6. In this study, we present integrated ML models of platin drug responses (cis-, carbo- 58 
and oxaliplatin), and evaluate them on clinical outcomes data that were not used to 59 
construct the signatures. Previous studies have reviewed the genes7, gene products8 60 
and specific individual pathways that are activated and repressed by drugs9, but lack 61 
comprehensive models of the global cellular response to drugs. We use integrated ML-62 
based signatures based on expression of multiple genes to predict key responses to 63 
each of these platin agents, for the first time, at different resistance levels.  64 
Cisplatin, carboplatin and oxaliplatin are each widely prescribed compounds for 65 
their antineoplastic effects. While each contains platinum to form adducts with tumour 66 
DNA, their effectiveness differs for specific types of cancers, such as bladder (cisplatin), 67 
ovarian (cisplatin and carboplatin) and colorectal cancer (oxaliplatin). Carboplatin differs 68 
in structure from cisplatin, exchanging the latter’s dichloride ligands with a CBDCA 69 
(cyclobutane dicarboxylic acid) group, while oxaliplatin is paired with both a DACH 70 
(diaminocyclohexane) ligand and a bidentate oxalate group. These chelating ligands 71 
have greater stability and solubility to aqueous solutions, which lead to differences in 72 
drug toxicity compared to cisplatin10. Oxaliplatin can be up to two times as cytotoxic as 73 
cisplatin, but it forms fewer DNA adducts11. The large hydrophobic DACH ligand which 74 
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overlaps the major groove is thought to prevent binding of certain DNA repair enzymes 75 
such as the POL polymerases, and may contribute to the low cross-resistance between 76 
oxaliplatin and cisplatin and carboplatin10. While all three drugs can enter the cell via 77 
copper transporters, organic cation transporters are oxaliplatin-specific and likely play a 78 
role in its efficacy in colorectal cancer (CRC) cells where these transporters are 79 
commonly overexpressed7. Oxaliplatin specifically plays a role in interfering with both 80 
DNA and RNA synthesis, unlike cisplatin which only infers with DNA12. It is these 81 
intrinsic properties between the platinum drugs which lead to differences in their activity 82 
and resistance profiles, despite their similar mode of action. 83 
 We derived gene signatures to predict drug response at different sensitivity and 84 
resistance levels for each of these agents. We and others have used supervised 85 
learning algorithms, including random forest models13; support vector machine (SVM) 86 
models6; neural networks14; and linear regression models5 to make these predictions. 87 
Pathway and network analysis of gene expression have been used to indicate hundreds 88 
of genes potentially up- and down-regulated upon cisplatin treatment15. Cisplatin-specific 89 
gene signatures have been developed with integrative approaches such as elastic net 90 
regression using inferred pathway activity of bladder cancer cell line data16. These 91 
methods have implicated genes that have not been described previously. Supervised ML 92 
with biochemically-relevant genes has also been useful for predicting drug response6. A 93 
concern with each of these ML approaches is that an insufficient number of samples 94 
coupled to a large number of features, i.e. gene expression changes, in each sample 95 
can result in overfitting of the model affecting its generalizability with other sources of 96 
data17. We therefore reduce the number of dimensions by selecting genes biologically 97 
relevant to the drugs under observation6,17. In this study, genes included in the final 98 
signatures have well-defined roles in their corresponding drug responses 99 
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(Supplementary References, Section A). Additional selection criteria are necessary 100 
when the number of genes implicated in peer-reviewed reports is still prohibitively large 101 
compared to sample size.  102 
Biochemically-inspired gene signatures have shown good performance in 103 
predicting treatment response. A paclitaxel ML signature based on tumor gene 104 
expression (GE) had a higher success predicting the pathological complete response 105 
rate (pCR 18) for sensitive patients (84% of patients with no / minimal residual disease) 106 
than gene signatures based on differential GE analysis6. For gemcitabine, a signature 107 
derived from both expression and copy number (CN) data from breast cancer cell lines 108 
was derived, and subsequently applied to analysis of nucleic acids from patient archival 109 
material. Multiple other outcome measures used to validate gene signatures include 110 
prognosis5, Miller-Payne response19, and disease recurrence. Binary SVM classifiers 111 
based on discrete time thresholds have been used to classify continuous outcome 112 
measures such as prognosis and recurrence. By contrast, pCR is simpler to interpret 113 
with binary SVM models. Nevertheless, differences in clinical recurrence have been 114 
noted between patients demonstrated with pCR and those who do not exhibit disease 115 
pathology18. This source of variability in defining patient response can confound 116 
transferability of SVM models between different datasets. 117 
We apply biochemically-inspired ML to predict and compare the cellular and 118 
patient responses to cisplatin, carboplatin and oxaliplatin. We train models and perform 119 
model selection for classification of platin resistance with cancer cell line data, and 120 
validate using patient GE and clinical outcome data. Our previous gene signatures 121 
derived from cell line data were based on median GI50 for each drug6. Models (i.e. gene 122 
signatures) learned and selected using the cell line data have not been re-trained prior to 123 
application on the patient data, since GI50 values are not available in patient samples. 124 
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This has been a necessary compromise; however, in this study, we derive different 125 
signatures at the highest vs. the lowest levels of drug resistance. A series of candidate 126 
gene signatures are derived by shifting the GI50 thresholds that distinguish sensitivity 127 
from resistance. The frequency of genes selected at median vs. extreme thresholds 128 
highlights pathways that most likely define these responses among different patient 129 
subsets. 130 
RESULTS 131 
Selection of Platin Drug Related Genes 132 
We documented genes in the peer-reviewed literature associated with drug 133 
effectiveness or response (Supplemental References, Section B). For cisplatin, 134 
carboplatin and oxaliplatin, this implicated 179, 90, and 288 genes, respectively (Suppl. 135 
Table S1). Multiple factor analysis (MFA) was used to determine which genes were 136 
correlated to GI50 in breast cancer cell lines through either GE and/or CN13, significantly 137 
reducing the sizes of the gene sets for cisplatin (N=39), carboplatin (N=28), and 138 
oxaliplatin (N=55). Genes with significant relationships to GI50 and direction of correlation 139 
(positive or inverse) are indicated in Figure 1. The diverse functions of these genes 140 
included apoptosis, DNA repair, transcription, cell growth, metabolism, immune system, 141 
signal transduction and membrane transport. Analysis of IC50 and GE levels for cisplatin-142 
treated bladder cancer cell lines confirmed these relationships evident from GI50 values 143 
of different breast cancer lines. IC50 values were related to GE for CFLAR, FEN1, 144 
MAPK3, MSH2, NFKB1, PNKP, PRKAA2, and PRKCA20. Similarly, separate bladder cell 145 
line IC50 values from the Genomics of Drug Sensitivity in Cancer project 146 
(http://www.cancerrxgene.org; N=17) were correlated with GE for CFLAR, FEN1, and 147 
NFKB1, in addition to ATP7B, BARD1, MAP3K1, NFKB2, SLC31A2 and SNAI1.  148 
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We performed MFA on the GI50 values for cisplatin, carboplatin and oxaliplatin, 149 
without consideration of either GE or CN. Responses to cis- and carboplatin were 150 
directly correlated (a 6.2º separation between vectors), but neither was related to the 151 
oxaliplatin response (Figure 2). Previous studies have shown that cisplatin-resistant cell 152 
lines are generally sensitive to oxaliplatin21–23. 153 
SVM-based signatures were initially derived for each platin drug from breast 154 
cancer cell line GE data. A 13-gene signature for cisplatin that predicts whether 155 
observed growth inhibition is above or below the median GI50 threshold (5.2% cross-156 
validation misclassification rate) consisted of BARD1, BCL2L1, FAAP24, CFLAR, 157 
MAP3K1, MAPK3, NFKB1, POLQ, PRKAA2, SLC22A5, SLC31A2, TLR4, and TWIST1. 158 
A similarly derived carboplatin signature included AKT1, ATP7B, EGF, EIF3I, ERCC1, 159 
GNGT1, HRAS, MTR, NRAS, OPRM1, RAD50, RAF1, SCN10A, SGK1, TIGD1, TP53, 160 
and VEGFB (10.4% cross-validation misclassification). For oxaliplatin, the final SVM 161 
gene signature consisted of AGXT, APOBEC2, BRAF, CLCN6, FCGR2A, IGF1, MPO, 162 
MSH2, NAGK, NAT2, NFE2L2, NOTCH1, PANK3, PRSS1, and UGT1A1 (2.1% cross-163 
validation misclassification). A cisplatin SVM generated from 17 bladder cancer cell lines 164 
in cancerRxgene resulted in 2 equally accurate signatures (with 11.8% cross-validation 165 
misclassification) consisting of either PNKP and PRKCA or ATP7B, CFLAR, FEN1, 166 
MAPK3, NFKB1 and SLC22A11. These gene signatures were not useful for predicting 167 
patient outcomes due to the limited size of the training set. 168 
GI50-Threshold Independent Modeling  169 
In our previous studies, we set median GI50 value as the threshold to 170 
distinguished drug resistance and sensitivity5,6. An important question is whether the 171 
genes contributing to drug response are consistent among different cell lines, each with 172 
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their own unique GI50 values. Different ML gene signatures were obtained by shifting the 173 
GI50 threshold, which changed the labels of resistant vs. sensitive cell lines. After feature 174 
selection, the compositions of the corresponding gene signatures for each threshold 175 
were compared. Finally, ensemble averaging of all of these optimized SVMs with 176 
Gaussian kernels were derived for different GI50 thresholds was used to create a single 177 
aggregated, threshold-independent, ML-based predictive model, comprised of all genes 178 
that were selected in any of the threshold-specific models (i.e. a composite gene 179 
signature).  180 
Kinase (MAPK3, MAP3K1) genes and apoptotic family members (BCL2, 181 
BCL2L1) were most the common in the cisplatin signatures at different GI50 thresholds, 182 
with consistent representation of error-prone and base-excision DNA repair genes as 183 
well (Figure 3A; Supplementary Table S2A). The kinases are more concentrated in 184 
signatures with lower drug sensitivity thresholds, whereas BCL2 and BCL2L1 are more 185 
ubiquitous at all levels. The error prone polymerases, POLD1 and POLQ, are more 186 
frequent in gene signatures with lower sensitivity thresholds, while the flap endonuclease 187 
FEN1 tends to be present at high levels of resistance. Thresholded gene signatures for 188 
carboplatin-related genes commonly contained the apoptotic family member AKT1, 189 
transcription regulation genes ETS2 and TP53, as well as cell growth factors VEGFB 190 
and VEGFC, although the latter was less common at lower sensitivity thresholds (Figure 191 
3B). Common oxaliplatin-related genes included transporters SLCO1B1 and GRTP1 (but 192 
not SLC47A1), transcription genes NFE2L2, PARP15 and CLCN6, as well as multiple 193 
metabolism-related genes (Figure 3C).  194 
GI50 thresholded ML models were also derived using the log-loss function to evaluate 195 
whether an alternative loss function (for classification) would differ significantly to the 196 
misclassification-based gene signatures (by both the distribution of selected genes and 197 
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by model accuracy to patient data). Log-loss penalizes false classifications, whose value 198 
ranges from zero (or completely accurate), to 1 (or completely inaccurate; 199 
Supplementary Table S3). The overall distribution of genes across GI50 thresholds has 200 
many distinct similarities with the gene signatures derived by misclassification. For both 201 
sets of cisplatin gene signatures, BCL2, BCL2L1 and FEN1 are common in low-to-202 
moderate GI50 thresholds, while NFKB1 is enriched at high thresholds (Figure 3A; Suppl. 203 
Figure 1A). For carboplatin, AKT1, VEGFB and VEGFC are similarly distributed across 204 
GI50 thresholds with both methods, although VEGFB is less densely represented in log-205 
loss based gene signatures at low GI50 values (Figure 3B; Suppl. Figure 1B). In both 206 
sets of oxaliplatin gene signatures, SIAE and SLC47A1 are represented at high densities 207 
across all GI50 thresholds, whereas ABCG2 is present less frequently (<50% inclusion; 208 
Figure 3C and Suppl. Figure 1C). There are differences between signatures selected by 209 
minimizing log-loss and misclassification rates. EGF and ERCC1 were selected at a 210 
greater frequency at a moderate carboplatin GI50 with log-loss, rather than by 211 
misclassification. Similarly, oxaliplatin signature genes, APOBEC2, HLA-B, LTA, and 212 
MPO, were selected considerably more often by log-loss. Therefore, while the 213 
misclassification and log-loss based gene signatures are not interchangeable, overall, 214 
they are quite similar to one another.  215 
Log-loss gene signatures were initially constructed either by (a) a modified 216 
version of the misclassification-based method, or (b) using the backwards feature 217 
selection (BFS) software described in Zhao et al. (2018)25. Multiple signatures with low 218 
log-loss values can have different compositions, consistent with the possibility that there 219 
may be various diverse gene combinations that can give rise to signatures with 220 
satisfactory performance. However, these signatures often contain a larger number of 221 
gene features than the misclassification-based signatures, and raised concerns that they 222 
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might be more prone to overfitting. The log-loss minimized gene signatures generated by 223 
both methods had comparable compositions. The median GI50 thresholded cisplatin 224 
gene signature generated by the log-loss modified software [ATP7B, BCL2L1, CDKN2C, 225 
CFLAR, ERCC2, ERCC6, FAAP24, FOS, GSTO1, GSTP1, MAP3K1, MAPK13, MAPK3, 226 
MSH2, MT2A, PNKP, POLD1, POLQ, PRKAA2, PRKCA, PRKCB, SLC22A5, SLC31A2, 227 
SNAI1, TLR4, TP63] shares 15/19 genes with the signature generated by the BFS 228 
software25 [ATP7B, BARD1, BCL2, BCL2L1, ERCC2, FAAP24, FEN1, FOS, MAP3K1, 229 
MAPK13, MAPK3, MSH2, MT2A, NFKB1, PNKP, POLQ, PRKCB, SLC22A5, SNAI1]).  230 
Impact of Features in Gene Signatures 231 
To determine the contribution of individual genes on overall cross-validation 232 
accuracy of a gene signature, each gene was excluded (independently), and model 233 
accuracy was reassessed within every SVM signature (Supplementary Tables S2A; S2B 234 
and S2C contain cis-, carbo- and oxaliplatin gene signatures, respectively). Elimination 235 
of ERCC2, POLD1, BARD1, BCL2, PRKCA and PRKCB consistently significantly 236 
increase misclassification error (average > 16% increase) in moderate threshold cisplatin 237 
SVMs (GI50 thresholds: 5.1 to 5.5). ERCC2 and POLD1 perform critical functions in 238 
nucleotide and base excision repair, respectively. PRKCA and PRKCB are paralogs with 239 
significant roles in signal transduction. BARD1 has been shown to reduce apoptotic 240 
BCL2 in the mitochondria26, and has a key role in genomic stability through its 241 
association with BRCA1. The genes NFKB1, NFKB2, TWIST1, TP63, PRKAA2, and 242 
MSH2 show a high variance in increased misclassification between different gene 243 
signatures. The variance of these genes may be due to epistatic interactions with other 244 
biological components, including the other genes in the SVM. For example, NFKB1 and 245 
NFKB2 are jointly included in 7 SVMs generated at a moderate GI50 threshold. There is 246 
evidence of possible epistasis in that the removal of either of these genes, but not 247 
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necessary both, will have a large impact in model misclassification rates (≥ 18.0% 248 
increase). The misclassification variance of NFKB1 with NFKB2, is significantly lower 249 
than in SVM gene signatures lacking NFKB2.  250 
Derivation of Gene Signatures from Bladder Carcinoma Patient Data 251 
Gene signatures derived with cell line data are to be validated on cancer patient 252 
data. To explore the similarities of the gene signatures to said patient data, we also 253 
developed SVMs using the cisplatin and/or carboplatin-treated TCGA (The Cancer 254 
Genome Atlas) bladder urothelial carcinoma patients, using post-treatment time to 255 
relapse as a surrogate criterion for different GI50 resistance thresholds (as performed in 256 
Mucaki et al. [2017]24; Supplementary Table S4). Similar trends to cell line SVMs are 257 
apparent: POLQ is frequently included in gene signatures with recurrence threshold of 258 
longer duration, while FEN1 is a marker of resistance, when time to relapse is shorter. 259 
However BCL2, which is present in a majority of breast cancer cell line SVMs, is present 260 
in only one gene signature derived from TCGA data. Similarly, MSH2 was rarely 261 
selected using cell lines, yet appears in nearly all patient derived SVMs with > 1 year 262 
recurrence. However, independently derived patient SVMs could not be used for any 263 
other analyses. 264 
Validation of Cell-line based Models against Cancer Patient Data 265 
GI50-thresholded modeling for each platin drug, generated with the breast cancer 266 
cell line data, produced 70 cisplatin, 83 carboplatin, and 83 oxaliplatin SVM gene 267 
signatures, respectively. In order to understand how the choice of GI50 threshold for 268 
training on cell line data impacts predictive accuracy when the resulting gene signatures 269 
are applied to patient outcomes, each of the thresholded gene signatures was applied to 270 
available platin-treated patient datasets27–31. In this study, cisplatin gene signatures were 271 
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validated on bladder cancer patient data, carboplatin signatures were validated on 272 
ovarian cancer patient data, and oxaliplatin signatures were validated on colorectal 273 
cancer patient data. While the available data did contain the necessary GE information, 274 
the clinical response metadata differed between studies. The response of bladder 275 
cancer patients to cisplatin was provided as survival post-treatment by Als et al.30, 276 
whereas colorectal cancer patients treated with oxaliplatin were categorized as 277 
responders and non-responders by Tsuji et al 31. TCGA provided two different measures 278 
which were used to assess predictive accuracy in our gene signatures – clinical 279 
response to chemotherapy and disease-free survival. Signature accuracy was found to 280 
be similar using either measure (Supplementary Table S5A); however recurrence and 281 
disease-free survival was used as the primary measure of response, as it was more 282 
consistently recorded among the TCGA data sets tested. Patients from Als et al. 30 with 283 
a ≥ 5 year survival post-treatment were labeled as sensitive to treatment. The 284 
differences between these metadata may, in part, contribute to differences in the 285 
prediction accuracy of the thresholded SVM gene signatures. 286 
At higher resistance thresholds for any platin drug (low GI50), where more cell 287 
lines are labeled sensitive, the positive class (disease-free survival) is correctly 288 
classified, while the negative class (recurrence) is highly misclassified (Suppl. Figures 2 289 
and 3). The reverse is true for gene signatures derived using lower resistance thresholds 290 
(high GI50). For these reasons, SVMs generated at these extreme thresholds were not 291 
very useful at predicting patient outcomes. When used to predict recurrence in the 292 
TCGA datasets, sensitivity and specificity appears to be maximized in gene signatures 293 
where the GI50 threshold for resistance was set near (but not necessarily at) the median 294 
(Suppl. Figure 2; Suppl. Tables S5A to 5C). While this pattern holds true for data from 295 
Tsuji et al.30, oxaliplatin gene signatures where GI50 thresholds were set above the 296 
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median could better separate primary and metastatic CRC patients (best signature 297 
predicting 92.6% metastatic and 60.7% primary cancers; Suppl. Table S5C). Although 298 
less consistent, cisplatin gene signatures generated with thresholds above median GI50 299 
performed better when evaluating the patient dataset from Als et al.30 (Suppl. Figure 3). 300 
Gene signatures were individually evaluated for their accuracy in TCGA patients 301 
using various recurrence times post-treatment to classify resistant and sensitive patients 302 
(0.5 - 5 years; Supplemental Table S6A-C). The best performing cisplatin signature 303 
(hereby identified as Cis1; Table 1) was able to accurately predict 71.0% of bladder 304 
cancer patients who recurred after 18 mo. (N=31; 58.5% accurate for disease-free 305 
patients [N=41]). The best performing carboplatin gene signature (designated Car1 306 
[Table 1]) predicted recurrence of ovarian cancer after 4 years at an accuracy of 60.2% 307 
(N=302; 61.0% accurate for disease-free patients [N=108]). For oxaliplatin, the best 308 
performing gene signature (designated Oxa1 [Table 1]) accurately predicted 71.6% of 309 
the disease-free TCGA CRC patients after one year (N=88; 54.5% accuracy predicting 310 
recurrence [N=11]). These gene signatures (based on GE measured by Affymetrix Gene 311 
Chip Human Exon 1.0 ST arrays), TCGA sample expression data, as well as SVMs 312 
based on bladder cell line data (based on expression measured by Affymetrix U133A 313 
microarray), were added to the online web-based SVM calculator 314 
(http://chemotherapy.cytognomix.com; introduced in Dorman et al. [2016]6) to predict 315 
platin response. 316 
The TCGA bladder cancer data set contained 19 patients treated with carboplatin 317 
(but not cisplatin), which enabled evaluation of the specificity of cisplatin models relative 318 
to patients not treated with this drug. The cisplatin model which best predicted outcomes 319 
of carboplatin-treated TCGA bladder patients was not Cis1 (the best performing cisplatin 320 
model) but rather Cis12 at two years post-treatment (80% accurate for responding 321 
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patients [N=5]; 93% for recurrent patients [N=14]). Cis12 contains 9 genes not present in 322 
Cis1 including ATP7B, which is a gene found in many of our carboplatin models. The 323 
presence of this gene may have a significant impact on the overall accuracy of Cis12 to 324 
the carboplatin-treated bladder cancer patients. We also evaluated these 19 patients to 325 
the carboplatin-specific gene signatures, and found the signature which best predicted 326 
the response of these patients (Car73) was 84% accurate for patients after 1 year of 327 
treatment (100% for responding patients [N=11]; 62.5% accuracy for recurrent [N=8]). 328 
Interestingly, Car73 shares the same ATP7B gene with Cis12. Two additional 329 
carboplatin gene signatures are tied for overall accuracy (84%; Car9 and Car51), but 330 
more successfully predict non-responsive patients (87.5%; 82% accuracy for responding 331 
patients). AKT1, ETS2, GNGT1, and VEGFB were shared among these carboplatin 332 
gene signatures.  333 
To evaluate the consistency in the response prediction of TCGA bladder cancer 334 
patients treated with cisplatin, distances from the hyperplane for all SVMs generated 335 
were determined for patients with short recurrence time (<6 mo., N=10; Supplementary 336 
Figure 4). Despite showing similar levels of resistance to treatment, distances differed 337 
between patients. While these patients would be expected to be indicated as highly 338 
cisplatin resistant (hyperplane distance < 0), two patients (TCGA-XF-A9SU and TCGA-339 
FJ-A871) were predicted sensitive across nearly all SVM gene signatures. Similar 340 
variation was also seen in patients with either a long recurrence time (>4 years) or no 341 
recurrence at all after 6 years (Suppl. Figure 5).  342 
An aggregate, threshold-independent model was generated for each individual 343 
platin drug at different GI50 thresholds through ensemble ML, which involves the 344 
averaging of hyperplane distances for each model to generate a composite score for 345 
each TCGA patient tested (i.e. a composite gene signature). Hyperplane distances 346 
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across all 70 cisplatin gene signatures were similar, with a mean score of -0.22 and a 347 
standard deviation of 3.5 hyperplane units (hu) across the set of patient data. The 348 
ensemble model classified disease-free bladder cancer patients with 59% accuracy 349 
and those with recurrent disease with 47% accuracy. Limiting ensemble averaging to 350 
only cisplatin gene signatures generated at a moderate GI50 threshold (ranging from 5.10 351 
to 5.50) did not significantly improve accuracy (44% for disease-free and 66% for 352 
recurrent patients; Suppl. Table S7A). For carboplatin, ensemble ML did not produce 353 
significantly better predictions than random, regardless of the GI50 threshold interval 354 
selected (Suppl. Table S7B) or the similar mean hyperplane distances (-0.11 +/- 3.9 hu). 355 
For oxaliplatin, the ensemble ML model (mean = -0.12 +/- 2.7 hu) was most accurate 356 
after 1 year (60% accuracy for disease-free and 73% for recurrent patients; Suppl. Table 357 
S7C). As in cisplatin, limiting this analysis to oxaliplatin SVM gene signatures with 358 
moderate GI50 thresholds did not significantly increase accuracy.  359 
K-Fold Cross-Validation 360 
The misclassification-based cisplatin, carboplatin and oxaliplatin gene signatures 361 
were also evaluated by k-fold cross-validation on TCGA bladder, ovarian and colorectal 362 
cancer patient data, respectively. This cross-validation is independent of cell line data; 363 
that is, the genes and hyper-parameters of signatures are used, but the GE data used is 364 
exclusively from patients. Patients were evenly distributed in 5 groups with an equal (or 365 
near-equal) ratio of disease-free and recurrent patients. The majority of the cisplatin 366 
gene signatures showed an overall accuracy > 50%. The cisplatin gene signature which 367 
performed best under the k-fold analysis (6-resistance level; BARD1, BCL2, BCL2L1, 368 
PRKAA2, PRKCA, PRKCB, TWIST1) showed an overall accuracy of 71.2% (84.4% 369 
accurate for sensitive and 53.9% accurate for resistant patients). The accuracy of the 370 
carboplatin and oxaliplatin gene signatures did not exceed 60%. In general, treating the 371 
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patient data as a held-out test set yielded higher performance estimates than training 372 
and evaluating the models on the patient data using k-fold cross-validation. 373 
Predicting cisplatin response in patients based on smoking history 374 
Tobacco smoking is known as the highest risk factor for the development of 375 
bladder cancer32. Head and neck cancer patients who smoke while undergoing cisplatin 376 
and radiotherapy treatment have been shown to have a shorter overall survival rate33. 377 
We therefore subdivided the patients based on their smoking history and tested the 378 
thresholded gene signatures (Supplementary Tables S8 and S9). When testing patients 379 
who were lifelong non-smokers, the prediction accuracy of Cis1 predicted all non-380 
smoking patients who were recurrent after 18 months as cisplatin-resistant (N=5). 381 
Prediction accuracy for disease-free patients was 57.1% (N=14). Another gene signature 382 
(Cis18; Suppl. Table S8) had performed equally as well for non-smokers, and these two 383 
gene signatures share the genes BCL2, BCL2L1, FAAP24, MAP3K1, MAPK13, MAPK3, 384 
and SLC31A2. Threshold independent analysis predicted disease-free equally well, but 385 
recurrence was less accurate (66.7%). Note that non-smokers make up a small subset 386 
of the patients tested (N=19). Threshold-independent prediction of recurrence in patients 387 
with a smoking history was 46% accurate (N=13), while disease-free patients were 388 
correctly predicted at a rate of 58% (N=19). Recurrence in these patients was best 389 
predicted by a gene signature built at the median GI50 threshold (Cis2). Accuracy 390 
improved for both disease-free (57.7% -> 61.9%) and recurrent patients (76.0% -> 391 
78.6%) when excluding patients who quit smoking more than 15 years before diagnosis. 392 
This SVM includes CFLAR and PRKAA2, genes which are not present in the two gene 393 
signatures which performed well for non-smokers. 394 
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To determine which genes in these gene signatures led to discordant predictions 395 
of patient outcome, we gradually altered the expression of each signature gene until the 396 
misclassification was corrected. Expression of MAP3K1, MAPK3, SLC22A5 and 397 
SLC31A2, when altered, corrected discordant predictions of patient outcome. Altering 398 
BCL2L1 expression was more likely to correct the discordant predictions of Cis1 (4 out 399 
of 5) than with Cis2 (2 out of 4). If the change exceeded ≥ 3-fold the highest/lowest 400 
expression of that gene and the prediction was still unchanged between different 401 
patients, the effect of that gene was considered to be minor. Expression of PRKAA2, 402 
NFKB1, NFKB2 and TWIST1 could not be altered sufficiently to correct a discordant 403 
prediction.  404 
Cytosine Methylation Levels of Genes in Cisplatin Models 405 
Tobacco smoking has a significant impact on cytosine methylation levels in the 406 
genome34. CpG island methylation has been associated with smoking pack years in a 407 
subset of the TCGA bladder urothelial carcinoma patients26. We suspected that the level 408 
of methylation measured in the SVMs which performed best for smoking and non-409 
smoking patients might differ, and with possible concomitant effects on GE. When 410 
ranking each gene from Cis1 by highest methylation and GE, 88 of 1080 patient: gene 411 
combinations showed the expected inverse correlation between methylation levels and 412 
GE (i.e. high methylation and low GE). Inverse correlation of methylation and GE was 413 
more common than direct correlation (i.e. high methylation and high GE; N=17). 414 
However, direct correlation was more common in patients with a recent smoking history 415 
(70.5%). This pattern was also observed for Cis2, which best predicted recurrence in 416 
smokers. In cases where methylation and GE are directly correlated, we propose that 417 
smoking may alter expression by other effects, e.g. mutagenic, rather solely than by 418 
epigenetic inactivation through methylation.  419 
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DISCUSSION 420 
Using gene expression signatures, we derived both GI50 threshold-dependent 421 
and -independent ML models which predict the chemotherapy responses for cisplatin, 422 
carboplatin and oxaliplatin, respectively. The cisplatin gene signature Cis1 423 
(Supplementary Table S6A) most accurately predicted response in bladder cancer 424 
patients after 18 months, and Car1 (Suppl. Table S6B) best predicted response in 425 
ovarian cancer patients after 4 years. Oxa1 (Suppl. Table S6C) more accurately 426 
predicted disease-free patients than recurrent disease at the one year treatment 427 
threshold. The thresholds which best represented time-to-recurrence differed between 428 
the platin drugs in each cancer type. Cisplatin gene signatures had noticeably improved 429 
performance when smoking history was taken into account. 430 
The three platin drugs produce distinctly different gene signatures. Initial gene 431 
sets exhibited some overlap between platin drugs (N=67 between any two platins), but 432 
very few of these were correlated by MFA of GI50 with multiple platin drugs (ATP7B, 433 
BCL2 and MSH2). BCL2L1, GSTP1, MAP3K1, MAPK3, MT1A, and MT2 were genes 434 
common to multiple platin drugs whose expression was correlated with cisplatin GI50 435 
values but not with carboplatin and/or oxaliplatin values. Similarly, genes correlating only 436 
to carboplatin GI50 included AKT1, EGF, ERCC1, KRAS, LIG3, MTHFR, MTR, RAD50, 437 
TP53, while genes correlating to only oxaliplatin GI50 included ATM, BCL2, CLCN6, 438 
ERCC2, ERCC6, and UGT1A1. Despite the close similarity between cisplatin and 439 
carboplatin GI50 response (see Figure 2), only one gene (ATP7B) was related by MFA to 440 
GI50 levels of both drugs. BCL2 and MSH2 correlated with both cisplatin and oxaliplatin 441 
GI50 (BCL2 did not correlate with carboplatin GI50). The increase in misclassification 442 
caused by the elimination of MSH2 from any gene signature in which it was present was 443 
significant; for example, misclassification of Cis14 and Oxa21 (Table 1) were increased 444 
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by 28.2% and 19.1%, respectively (Suppl. Tables S2A and S2C). These differences may 445 
reflect the spectrum of activity, sensitivity, and toxicity of these signature genes21–23,35,36.  446 
Previous validation of patient data for other drugs validated with other datasets6,24 447 
using biochemically inspired machine learning have had better performance than those 448 
reported here. We investigated the possibility that disease and molecular heterogeneity 449 
in platin-treated patients may have affected the accuracy of our results. Model 450 
predictions were reevaluated after stratifying clinical features such as time-to-disease 451 
recurrence, cancer stage, and metastatic lymph node count. Breast cancer patients with 452 
advanced disease (stage III and IV) were analyzed separately from those with earlier 453 
stage diagnoses (stage I and II). Cisplatin gene signature Cis1 performed best on stage 454 
IV patients (overall accuracy 72.4% at a 2 year recurrence threshold), while Oxa1 455 
similarly performed best in predicting late stage cancers (74.5% accurate for stage III 456 
and 71.4% accurate for stage IV at a 2 year recurrence threshold). Cis5 was also more 457 
accurate for later stage cancer patients (72.4% overall accuracy at 18 months). The 458 
accuracies of gene signatures were similar across all stages (e.g. Car1 ranged from 58-459 
74%). Cisplatin-treated, TCGA bladder cancer patients and oxaliplatin-treated TCGA 460 
colorectal cancer patients were also stratified by Lymph Node status (N0, N1, and N2 461 
[bladder cancer patient data set comprised of only two N3 patients, which were included 462 
with the analysis of N2 patients; N3 was not represented in colorectal cancer]). In TCGA 463 
bladder cancer patients, Cis1 exhibited ~60% accuracy across all categories; however it 464 
performed better in sensitive N0 and N1 patients relative to N2. Cis2 was less accurate 465 
for N2 patients than for N0 and N1. Sensitive N2 patients were more likely to be 466 
misclassified (<40%) than relapsed N2 patients. In TCGA colorectal cancer patients, 467 
Oxa1 was 88% accurate in N2 patients (95% accurate for sensitive N2 patients [n=19], 468 
and 67% accurate for relapsed N2 patients [n=6]). Oxaliplatin gene signatures were less 469 
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accurate for N1 patients compared to N0 and N2. Thus, heterogeneity in disease stage 470 
as well as metastatic phenotypes adversely confounds the overall accuracies of our 471 
predictions.  472 
Gene signature models derived from cell lines and tested on patients differ in 473 
their outcome measures. The exact GI50 cell line threshold that is most predictive of 474 
patient outcome is not known, and different groups use different methods to discretize 475 
GI50 values37,38. Therefore, we developed ML models for platin drugs which predict drug 476 
response without relying on arbitrary GI50 thresholds. For cisplatin, SVM ensemble 477 
averaging generated on different resistance thresholds shows a small increase in 478 
accuracy over most gene signatures, better representing the sensitive, disease-free 479 
class (59% accuracy). Interestingly, ensemble averaging of only the gene signatures 480 
built using a moderate GI50 thresholds yielded results which better represented the 481 
resistance class. This result closer matches the accuracy of Cis1, and may be due to 482 
Cis1 having a greater overall impact on the ensemble prediction. When limiting 483 
ensemble averaging to only those gene signatures with the highest area under the curve 484 
(AUC) at each resistance threshold, differences in predictions were negligible. Ensemble 485 
ML can potentially avoid problems with poor performance and overfitting by combining 486 
gene signatures that individually perform slightly better than chance39.  487 
  It is difficult to reconcile gene signatures without features known to be related to 488 
chemoresistance with tumor biology. Our thresholding approach may reveal potentially 489 
important genes and pathways associated with platin resistance. It would be preferable 490 
to explore pathways related to signature genes to improve accuracy, identify potential 491 
targets for further study of chemoresistance, and expand the model parameters to take 492 
into account alternate states besides those captured in the original signature40. 493 
Signatures for resistance may be useful for developing targeted intervention to re-494 
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sensitize tumours. For example, the mismatch repair (MMR) gene MSH2 is commonly 495 
present in gene signatures at high resistance levels for oxaliplatin, which is of interest, 496 
as MMR deficiency has been shown to be predictive for oxaliplatin resistance36. Indeed, 497 
MLH1, MSH2 and MSH6-deficient cells are more susceptible to oxaliplatin, despite 498 
MMR-deficiency being associated with cisplatin resistance35. The autoimmune disease-499 
associated gene SIAE, which has been previously shown to have a strong negative 500 
correlation to oxaliplatin response in advanced CRC patients41, was selected in the 501 
majority of thresholded oxaliplatin gene signatures (Supplementary Table S2C). The 502 
gene BCL2, which was commonly selected for cisplatin (Figure 3A), was rarely selected 503 
for oxaliplatin (Figure 3C). At the highest levels of resistance to cisplatin, gene 504 
signatures were enriched for genes belonging to DNA repair, anti-oxidative response, 505 
apoptotic pathways and drug transporters (Figure 3A). These gene pathways are known 506 
to be involved in cisplatin resistance42,43 and these specific genes may be explored in 507 
subsequent work to identify the contribution to chemotherapy response in a biochemical 508 
context.  509 
  Log-loss evaluates the accuracy of a classifier by penalizing erroneous 510 
classifications, and is relevant in cases where data is imbalanced and/or have an 511 
unequally distributed error cost. We assessed whether ML gene signatures based on 512 
log-loss minimization could improve accuracy to predicting patient response 513 
(Supplementary Table S3) and compared them to gene signatures generated by 514 
minimizing cell line misclassification. When gene signatures generated by both methods 515 
were highly similar (generated at the same GI50 threshold, consist of a similar number of 516 
genes and consist of ≥ 80% shared genes), prediction accuracy of TCGA cancer patient 517 
outcomes were nearly indistinguishable, as accuracy can vary over different relapse 518 
thresholds. Where significant differences in predictions were seen, the misclassification-519 
based gene signatures were more accurate overall (Cis1, Cis17 and the “12-Resistant” 520 
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carboplatin gene signature were +8.3%, +5.6% and +3.9% more accurate compared to 521 
the log-loss gene signature, respectively). Oxaliplatin gene signatures were dissimilar 522 
across all GI50 thresholds, as the log-loss minimized ML gene signatures often contain 523 
increased numbers of genes compared to the misclassification-based gene signatures. 524 
Many of these larger gene signatures were less accurate in patients compared to gene 525 
signatures which minimized misclassification rates consistent that this evaluation and 526 
model selection method is more prone to overfitting. This pattern was also noted for 527 
gene signatures generated at extreme GI50 thresholds for all three platin drugs in which 528 
response was, by definition, somewhat imbalanced. 529 
It may be feasible to predict responses to combination chemotherapy with the 530 
gene signatures described here. Not included in the present analysis were signatures for 531 
methotrexate, vinblastine, and doxorubicin, which comprise the MVAC cocktail used to 532 
treat bladder cancer. This was due primarily to a lack of patients treated with this drug 533 
combination in the TCGA bladder dataset (N=11). Individual signatures for several of 534 
these drugs have been derived and analyzed using the patient data from METABRIC 535 
(Molecular Taxonomy of Breast Cancer International Consortium)24. A reasonable 536 
approach to predicting combination chemotherapy would first determine the probability 537 
of sensitivity or resistance to individual drugs, accounting for the misclassification rate by 538 
each (defined as d1, …, dk). The ML classifiers output these probabilities, analogous to 539 
their misclassification rates in a set of patients treated identically. If the model predicts 540 
that the patient is sensitive to drug d1 with 90% probability, and sensitive to drug d2 with 541 
5% probability, and the errors are independent, then the probability of sensitivity to the 542 
combination is 1 - (1 - 0.9)*(1 - 0.05) = 90.5%, and the probability of resistance is 9.5%, 543 
assuming no synergistic effects between drugs. If interaction or dependence among 544 
errors is suspected, the combined probability of resistance to the pair d12 could be 545 
estimated based on the features that are shared by the signatures of both drugs. The 546 
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probability of sensitivity to the combination would then be given by 1 - (1 - d12)*(1 - 547 
d3)*…*(1 - dk).  548 
The predictive accuracy for the same gene signature could differentiate highly 549 
between the two datasets. Cis3 (Supplemental Table S6A) had an AUC of 0.64 when 550 
validated against TCGA bladder cancer patients. However, the AUC was lower when 551 
applied to the Als et al.29 dataset (AUC=0.18). Patient metadata in the latter study only 552 
indicated patient survival times, while we base the expected TCGA patient outcome on 553 
time to disease recurrence. As the basis of our expected outcome differs between 554 
datasets, these differences may be acting as a confounding factor to determine accuracy 555 
of gene signatures. The datasets also differ in how expression was measured 556 
(microarray vs. RNA-seq). The relevance of gene signatures based on training and 557 
testing data from different platforms can affect the accuracy of validation, which might 558 
not be improved by data normalization. In this study, datasets were subjected to z-score 559 
normalization. In subsequent studies, other techniques to correct for some of these 560 
effects have been described and could be applied44. 561 
In summary, we describe GI50- or IC50-threshold-independent ML gene signatures 562 
to predict chemotherapy response to platin agents in cancer patients. Ensemble 563 
machine learning produced combined signatures that were more accurate than most 564 
individual gene signatures generated with different thresholds. Genes associated 565 
cisplatin response included those which exacerbate resistance in patients with a history 566 
of smoking. The methodology described here should be adaptable to other drugs and 567 
cancer types. With a range of gene signatures for multiple drugs, it may be possible to 568 
improve the efficacy of treatment by tailoring treatment to a patient's specific tumour 569 
biology, and reduce treatment duration by limiting the number of different therapeutic 570 
regimens prescribed before achieving a successful response45. 571 
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MATERIALS AND METHODS 572 
Data and preprocessing 573 
Cell-line Data Sets 574 
Microarray GE and data were from breast cancer cell lines were used to train 575 
ML-based gene signatures of drug response based on respective growth or target 576 
inhibition data (GI50 or IC50). Cell lines were treated with either cisplatin (N=39), 577 
carboplatin (N=46), or oxaliplatin (N=47)13. Bladder cancer cell line GE and IC50 578 
measurements for cisplatin were obtained from cancerRxgene (N=17). However, all 579 
models (gene signatures) used to evaluate patient data were trained on breast cancer 580 
cell line data, because the number of bladder cancer cell lines was insufficient to 581 
produce accurate signatures.  582 
Cancer Patient Data Sets 583 
RNA-seq GE and survival measurements were downloaded from TCGA for 584 
bladder urothelial carcinoma (N=72 patients treated with cisplatin)26, ovarian epithelial 585 
tumor (N=410 treated with carboplatin)27 and colorectal adenocarcinoma (N=99 treated 586 
with oxaliplatin)28. GE of cisplatin-treated patients of cell carcinoma of the urothelium 587 
(N=30)29 and for oxaliplatin-treated CRC patients (N=83)30 were obtained from the Gene 588 
Expression Omnibus. Clinical metadata and GE for TCGA patients were obtained from 589 
Genomic Data Commons (https://gdc.cancer.gov/), while methylation HM450 (Illumina) 590 
data for these patients was downloaded from cBioPortal46. 591 
Development and Pre-Processing of Biochemically-Inspired Gene Sets 592 
Initial gene sets for developing signatures for each drug were identified from 593 
previously published literature (see Supplemental References, Section B) and 594 
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databases, such as PharmGKB and DrugBank47,48. The evidence supporting each gene 595 
contained in the final signatures is independent scientific evidence that the genes 596 
selected are not the result of spurious associations. The final gene sets were chosen 597 
using MFA with the breast cancer cell-line data to analyze interactions between GE, CN, 598 
and GI50 data for the drug of interest49. Genes whose GE and/or CN showed a direct or 599 
inverse correlation with GI50 were selected for SVM training. Because the number of 600 
genes related to GI50 for oxaliplatin exceeded the number of cell lines available for 601 
training, we limited the input to the oxaliplatin ML model to those genes whose GE were 602 
related to GI50. Similarly, the number correlating genes in cisplatin treated cells 603 
exceeded the number of cell lines. For cisplatin, genes whose expression correlated with 604 
GI50 were eliminated if they showed no or little expression in TCGA bladder cancer 605 
patients (i.e. RNA-seq counts by Expectation Maximization [RSEM] were < 5.0 for 606 
majority of individuals). This reduces the overall number of genes for SVM analysis, and 607 
thus helps to avoid a data to size sample imbalance. For cisplatin, MFA was repeated 608 
using IC50 values for 17 bladder cancer cell lines; however, the available CN data 609 
generally showed a lack of variation in the cell lines for these genes. Instead, the 610 
available IC50 values for three other cancer drugs (doxorubicin, methotrexate and 611 
vinblastine) were compared with the IC50 of cisplatin by MFA.  612 
Applying an SVM model directly to patient data without a normalization approach 613 
is imprecise when training and testing data are not obtained using similar methodology 614 
(i.e. different microarray platforms). To compare the cell line GE microarray data and the 615 
patient RNA-seq GE datasets, expression values were normalized by conversion to z-616 
scores using MATLAB50. Although Log2 intensity values from microarray data were not 617 
available for TCGA samples, RNA-seq based GE and log2 intensities from microarray 618 
data are highly correlated51. 619 
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Machine Learning 620 
SVMs were trained with breast cancer cell line GE datasets13 with the Statistics 621 
Toolbox in MATLAB50 similar to Dorman et al (2016)6. Rather than a linear kernel, we 622 
used a Gaussian kernel function (fitcsvm), and then tested with leave-one-out cross-623 
validation (using the options ‘crossval’ and ‘leaveout’). A greedy backwards feature 624 
selection algorithm was used to improve classification accuracy52. BFS leaves out 625 
individual genes from the initial MFA-qualified gene set, then trains a cross validated 626 
Gaussian kernel SVM on the training samples, removing the gene with the highest 627 
misclassification rate. The procedure is repeated until all genes have been evaluated. 628 
The gene subset with the lowest misclassification rate6 or log-loss statistic25 based on 629 
cross-validation is selected as the gene signature for subsequent testing with patient GE 630 
and clinical data. K-fold cross validation of the misclassification-based gene signatures 631 
was performed using MATLAB software described in Zhao et al. (2018)25. 632 
SVMs minimized according to the log-loss classification function were also 633 
generated with both software described in Zhao et al. (2018; uses multiclass compatible 634 
'fitcecoc' function)25, and with a modified version of the software described above (using 635 
‘fitSVMPosterior’ to compute posterior probabilities). Computed probabilities differ 636 
between 'fitSVMPosterior' and 'fitcecoc' (range: 0.02-0.04), thus the resultant gene 637 
signatures will differ between the two programs. When given unbalanced data (e.g. 638 
lower resistance thresholds), ‘fitSVMPosterior’ will warn that some classes are not 639 
represented, and thus those folds will not predict the labels for those missing classes. 640 
The log-loss gene signatures described in this manuscript were generated with the 641 
multiclass compatible 'fitcecoc' function software25. 642 
Derivation of gene signatures for different drug resistance thresholds  643 
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We have previously set a conventional GI50 threshold distinguishing sensitivity 644 
from resistance at the median of the range of drug concentrations that inhibited cell 645 
growth by 50%6. We hypothesized that different gene signatures could be derived for 646 
different levels of drug resistance by varying this threshold. ML experiments for 647 
classifying resistance or sensitivity at GI50 values generated a series of optimized 648 
Gaussian SVM gene signatures whose performance were assessed with patient 649 
expression data for each signature. A heat map which illustrates the frequencies of 650 
genes appearing in these gene signatures was created with the R language hist2d 651 
function.  652 
A composite gene signature was created by ensemble averaging of all gene 653 
signatures generated at each resistance threshold. Ensemble averaging combines 654 
signatures through averaging the weighted accuracy of a set of related models39. The 655 
decision function for the ensemble classifier is the mean of the decision function scores 656 
of the component classifiers, weighted by the AUC.  657 
Significance of cell line-derived gene signatures 658 
The significance of the derived SVMs (whether the observed performance of the 659 
gene signatures could have arisen by chance) was first assessed by permutation 660 
analysis with randomized cell line labels and with random sets of genes, as described 661 
previously6. Using the median cisplatin GI50 as the resistance threshold, 10,000 gene 662 
signatures based on random gene selection (15 genes) had higher rates of 663 
misclassification than the best median SVM gene signatures (2 signatures with 7.7% 664 
misclassification). Cisplatin, carboplatin and oxaliplatin GE data for random cell line label 665 
combinations (n=10,000) generated only 8, 1 and 1 signatures, respectively, with lower 666 
error rates than the best biochemically-inspired signatures. When minimizing for log-loss 667 
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(rather than misclassification), random gene analysis (10,000 iterations; median cisplatin 668 
GI50 threshold) resulted only in gene signatures with a higher log-loss than the signature 669 
generated with the initial cisplatin gene set. Log-loss based random label analysis 670 
(n=2000 combinations) resulted in 3.4% of random label gene signatures resulted in a 671 
lower log-loss than the cisplatin signature at the same GI50 threshold (5.27).This was not 672 
entirely surprising, since this result depends on the GI50 threshold used for labeling. The 673 
differences between GI50 values for cell lines close to the median GI50 used in this 674 
analysis are almost negligible (e.g. 5.11 vs 5.12) and likely within the measurement error 675 
for these values.  676 
Regarding the specificity of the cisplatin gene signatures, the best performing 677 
cisplatin gene signatures (Cis1 and Cis2) were used to evaluate participants who were 678 
treated with other drugs (using an 18 months post-treatment threshold). In such patients, 679 
36.5% of those who were disease-free were predicted accurately with the Cis1 signature 680 
(N=178; 22% less accurate than platin-treated patients), and 62.9% accurate for those 681 
with recurrent disease (N=70; 8.1% less accurate). Cis2 was 43.8% accurate for 682 
disease-free non-platin treated patients (N=178; 12.3% lower accuracy), and 60.0% of 683 
those who relapsed (N=70; 2.9% less accurate). GE changes in patients treated with 684 
platin drugs are better modeled by cancer cell-line based predictors than in patients 685 
receiving other drug treatments.  686 
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Tables 826 
Table 1: Gene Signatures Which Best Predicted Response in TCGA Cancer Patients 827 
Gene 
Signature ID 
Cancer Type 
Tested 
GI50 
Threshold Signature (C, σ*) 
Cis1 
(Cisplatin) Bladder 5.11 
BARD1, BCL2, BCL2L1, CDKN2C, FAAP24, FEN1, 
MAP3K1, MAPK13, MAPK3, NFKB1, NFKB2, 
SLC22A5, SLC31A2, TLR4, TWIST1 (100000, 100) 
Cis2 
(Cisplatin) Bladder 5.12 
BARD1, BCL2L1, CFLAR, FAAP24, MAP3K1, MAPK3, 
NFKB1, POLQ, PRKAA2, SLC22A5, SLC31A2, TLR4, 
TWIST1 (10000, 100) 
Cis3 
(Cisplatin) Bladder 5.60 
BCL2, CFLAR, ERCC2, ERCC6, FAAP24, FEN1, 
MAP3K1, NFKB1, NFKB2, PNKP, POLQ, PRKCB, 
SLC22A5, SNAI1, TLR4 (100000, 100) 
Cis12 
(Cisplatin) Bladder 5.40 
ATP7B, BCL2, BCL2L1, CDKN2C, ERCC2, FAAP24, 
GSTO1, MAP3K1, MAPK3, MT2A, NFKB1, NFKB2, 
POLD1, POLQ, PRKCB, SNAI1, TLR4, TP63 (10000, 
100) 
Cis14 
(Cisplatin) Bladder 5.16 
BARD1, BCL2, BCL2L1, CDKN2C, FAAP24, FEN1, 
FOS, GSTP1, MAP3K1, MAPK13, MAPK3, MSH2, 
NFKB1, POLD1, POLQ, PRKAA2, PRKCB, SLC22A5, 
SLC31A2, SNAI1, TWIST1 (10000, 100) 
Cis17 
(Cisplatin) Bladder 5.10 
ATP7B, BCL2, BCL2L1, FEN1, GSTP1, MAP3K1, 
MAPK3, MT2A, NFKB1, PNKP, POLQ, PRKAA2, 
PRKCB, SLC31A2, TLR4, TP63 (100000, 100) 
Car1 
(Carboplatin) Ovarian 4.22 
AKT1, EIF3K, ERCC1, GNGT1, GSR, MTHFR, 
NEDD4L, NLRP1, NRAS, RAF1, SGK1, TIGD1, TP53, 
VEGFB, VEGFC (100000, 100) 
Car9 
(Carboplatin) Ovarian 4.32 
AKT1, ATP7B, EIF3I, ETS2, GNGT1, HRAS, KRAS, 
LIG3, MTHFR, MTR, NRAS, RAD50, SCN10A, TIGD1, 
TP53, VEGFB (10000, 100) 
Car51 
(Carboplatin) Ovarian 4.34 
AKT1, EGF, EIF3I, ERCC1, ETS2, GNGT1, KRAS, 
MTHFR, MTR, NEDD4L, NLRP1, NRAS, RAD50, 
RAF1, SGK1, TIGD1, TP53, VEGFB, VEGFC (10000, 
100) 
Car73 
(Carboplatin) Ovarian 4.09 
AKT1, ATP7B, ETS2, GNGT1, HRAS, NLRP1, 
SCN10A, VEGFB (100000, 1000) 
Oxa1 
(Oxaliplatin) Colorectal 5.10 
BRAF, FCGR2A, IGF1, MSH2, NAGK, NFE2L2, NQO1, 
PANK3, SLC47A1, SLCO1B1, UGT1A1 (10, 10) 
Oxa21 
(Oxaliplatin) Colorectal 5.10 
BRAF, IGF1, IGF1R, KLF3, MSH2, NAT2, NFE2L2, 
NQO1, PANK3, PRSS1, SIAE, SLC47A1, SLCO1B1, 
UGT1A1 (1000, 100) 
*C - The box-constraint. σ – the kernel-scale (“sigma”). Bolded gene signatures are those that best overall 
performance against TCGA cancer patient gene expression data. 
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 829 
FIGURE LEGENDS 830 
Figure 1. Schematic of platinum drug sensitivity and resistance genes which showed 831 
MFA correlation for GI50 of A) cisplatin, B) carboplatin, and C) oxaliplatin. The genes 832 
used to derive the SVM are shown in context of their effect in the cell and role in cisplatin 833 
mechanisms of action. GE and CN correlation with inhibitory drug concentration by MFA 834 
of breast (GI50) and bladder (IC50) cancer cell line data.  835 
Figure 2: GI50 values for cell lines treated with the three platin drugs were plotted in 836 
order of ascending oxaliplatin GI50. For most cell lines, there is a visible trend between 837 
the GI50 for cisplatin and carboplatin, reflecting the correlation between the two drugs 838 
seen by MFA. Despite this correlation, carboplatin shows a much smaller variance (0.22) 839 
compared to cisplatin (0.37; oxaliplatin variance is 0.34). 840 
Figure 3. The variation in gene composition of misclassification-based SVMs at different 841 
GI50 thresholds for A) cisplatin, B) carboplatin, and C) oxaliplatin. GI50 intervals are 842 
indicated on the left, with the number of cell lines with GI50 values within said intervals in 843 
brackets. Each box represents the density of genes appearing in optimized Gaussian 844 
SVM gene signatures in those functional categories, with darker grey indicating frequent 845 
genes in indicated GI50 threshold intervals, while lighter grey indicates less commonly 846 
selected genes. The number of thresholded gene signatures used to derive the density 847 
plot within each interval is equal (or greater, in the case of multiple equally performing 848 
gene signatures) to the number of cell lines within that GI50 interval. 849 
Supplementary Figure 1. The variation in gene composition of log-loss based SVMs at 850 
different GI50 thresholds for A) cisplatin, B) carboplatin, and C) oxaliplatin. Each box 851 
represents the density of genes appearing in optimized Gaussian log-loss SVM gene 852 
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signatures in those functional categories, with darker grey indicating frequent genes in 853 
indicated GI50 threshold intervals, while lighter grey indicates less commonly selected 854 
genes. 855 
Supplementary Figure 2. Classification accuracy of gene signatures on TCGA bladder 856 
cancer patients treated with cisplatin and/or carboplatin as the resistance threshold is 857 
varied. Recurrence and disease-free survival are used as a binary measure to assess 858 
performance. The x-axis indicates movement of the resistance threshold, with more cell 859 
lines labeled sensitive on the left and more labeled resistant on the right. Maximal AUC 860 
is indicated by the downward arrows. 861 
Supplementary Figure 3. Classification accuracy of SVM gene signatures for cisplatin, 862 
at a range of response thresholds, were assessed using gene expression data for 863 
cisplatin-treated bladder cancer patients from Als et al. 29. Patients with a ≥ 5 year 864 
survival post-treatment were labeled sensitive. Red arrows indicate the SVM gene 865 
signatures with the highest positive predictive value (PPV) in the accuracy of 866 
classification of patient outcome.  867 
Supplementary Figure 4. Hyperplane distance calculated by all thresholded SVMs for 868 
recurrent (<6 months) TCGA patients. Each diagram represents the predictions of all 869 
SVMs for all patients who had recurrence less than 6 months after treatment (N=10). 870 
Each point represents an SVM, where the x-axis represents the number of cell lines set 871 
to resistant (in order of lowest to highest GI50), and the y-axis represents the calculated 872 
hyperplane distance. A negative hyperplane distance would represent a prediction of 873 
resistance to cisplatin. Despite this, some patients show a strong preference towards 874 
predictions of sensitivity (i.e. TCGA-XF-A9SU). 875 
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Supplementary Figure 5. Hyperplane distance calculated by all thresholded SVMs for 876 
sensitive TCGA patients. Each diagram represents the predictions of all SVMs for all 877 
patients who had recurrence > 4 years after treatment (top; N=3), or patients who 878 
showed no recurrence after 6 years (bottom; N=6). Each point represents an SVM, 879 
where the x-axis represents the number of cell lines set to resistant (in order of lowest to 880 
highest GI50), and the y-axis represents the calculated hyperplane distance. A positive 881 
hyperplane distance would represent a prediction of sensitivity to cisplatin.  882 
Supplementary References. A) Experimental evidence supporting inclusion of genes 883 
using references relating expression to platinum drug efficacy. A subset of genes are 884 
shown with consistent significant increase in misclassification error. B) The initial peer-885 
reviewed literature used to develop gene signatures associated with cis-, carbo- and 886 
oxaliplatin response.  887 
Supplementary Tables. Details of gene signatures, validation, and accuracy are  888 
indicated in Tables: S1A) Genes Selected for MFA of Expression/Copy Number to 889 
Cisplatin GI50; S1B) Genes Selected for MFA of Expression/Copy Number to 890 
Carboplatin GI50; S1C) Genes Selected for MFA of Expression/Copy Number to 891 
Oxaliplatin GI50; S2A) SVM Models by Varying Resistance Thresholds and Impact on 892 
Misclassification, Categorized by Gene Function for Cisplatin; S2B) SVM Models by 893 
Varying Resistance Thresholds and Impact on Misclassification, Categorized by Gene 894 
Function for Carboplatin; S2C) SVM Models by Varying Resistance Thresholds and 895 
Impact on Misclassification, Categorized by Gene Function for Oxaliplatin; S3A) 896 
Cisplatin SVM Models Derived Over a Range of Response Thresholds Using Log-Loss 897 
Minimization; S3B) Carboplatin SVM Models Derived Over a Range of Response 898 
Thresholds Using Log-Loss Minimization; S3C) Oxaliplatin SVM Models Derived Over a 899 
Range of Response Thresholds Using Log-Loss Minimization; S4) SVM Models 900 
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Generated by Bladder Cancer Patient Data at Various Time to Recurrence thresholds, 901 
Categorized by Gene Function for Cisplatin; S5A) Cisplatin SVM Models Derived Over a 902 
Range of Response Thresholds for TCGA Bladder Cancer Patients using 903 
Misclassification; S5B) Carboplatin SVM Models Derived Over a Range of Response 904 
Thresholds for TCGA ovarian epithelial tumor patients using Misclassification; S5C) 905 
Oxaliplatin SVM Models Derived Over a Range of Response Thresholds for TCGA 906 
colorectal adenocarcinoma patients using Misclassification; S6A) Accuracy of SVMs for 907 
TCGA Bladder Cancer Patients, in relation to Time to Recurrence Post-Treatment With 908 
Cisplatin; S6B) Accuracy of SVMs for TCGA Bladder Cancer Patients, in relation to Time 909 
to Recurrence Post-Treatment With Carboplatin; S6C) Accuracy of SVMs for TCGA 910 
Bladder Cancer Patients, in relation to Time to Recurrence Post-Treatment With 911 
Oxaliplatin; S7A) Accuracy of Threshold Independent Analysis (Ensemble Averaging) for 912 
Cisplatin; S7B) Accuracy of Threshold Independent Analysis (Ensemble Averaging) for 913 
Carboplatin; S7C) Accuracy of Threshold Independent Analysis (Ensemble Averaging) 914 
for Oxaliplatin; S8) Accuracy of SVMs for Non-Smoking TCGA Bladder Cancer Patients; 915 
S9) Accuracy of SVMs for Smoking TCGA Bladder Cancer Patients (within 15 years of 916 
diagnosis). 917 







